{"transactions":[{"id":1152176,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-12T17:34:31.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":17100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a grant of restricted stock units that vests on May 08, 2026."}],"balance_after":219815,"source":{"system":"sec-edgar","filing":"0001722482-25-000152","document":"wk-form4_1747085662.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000172248225000152/wk-form4_1747085662.xml","form_type":"4"}},{"id":1163859,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-29T17:58:18.000Z","date":"2025-04-28","kind":"purchase","planned":false,"acquired":true,"shares":8091,"price":12.81,"value":103645.71,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average trading price of share purchased on the transaction date. The range for the purchase of the shares was $12.36 and $12.83."}],"balance_after":202715,"source":{"system":"sec-edgar","filing":"0001722482-25-000092","document":"wk-form4_1745963891.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000172248225000092/wk-form4_1745963891.xml","form_type":"4"}},{"id":1519059,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-13T16:28:51.000Z","date":"2024-05-09","kind":"grant","planned":false,"acquired":true,"shares":8477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a grant of restricted stock units that vests on May 09, 2025."}],"balance_after":194624,"source":{"system":"sec-edgar","filing":"0001722482-24-000114","document":"wk-form4_1715632120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000172248224000114/wk-form4_1715632120.xml","form_type":"4"}},{"id":1893481,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-15T16:45:43.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":9808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a grant of restricted stock units that vests on May 11, 2024."}],"balance_after":186147,"source":{"system":"sec-edgar","filing":"0001722482-23-000117","document":"wf-form4_168418352647352.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000172248223000117/wf-form4_168418352647352.xml","form_type":"4"}},{"id":2270317,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-16T18:13:54.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":6693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a grant of restricted stock units that vests on May 12, 2023."}],"balance_after":176339,"source":{"system":"sec-edgar","filing":"0001722482-22-000124","document":"wf-form4_165273915693341.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000172248222000124/wf-form4_165273915693341.xml","form_type":"4"}},{"id":2304422,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T16:59:17.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":1215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a grant of restricted stock units that vests on May 11, 2022."}],"balance_after":169646,"source":{"system":"sec-edgar","filing":"0001722482-22-000086","document":"wf-form4_164919233594043.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000172248222000086/wf-form4_164919233594043.xml","form_type":"4"}},{"id":2761252,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T16:10:16.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":15308,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"RSAs fully vested on grant date."}],"balance_after":157033,"source":{"system":"sec-edgar","filing":"0001415889-21-001827","document":"form4-04022021_040402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000141588921001827/form4-04022021_040402.xml","form_type":"4"}},{"id":2826418,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-01T17:38:22.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":7236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a grant of restricted stock units that vests on February 25, 2022."}],"balance_after":168431,"source":{"system":"sec-edgar","filing":"0001722482-21-000099","document":"wf-form4_161463828573565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000172248221000099/wf-form4_161463828573565.xml","form_type":"4"}},{"id":3249373,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-25T17:29:04.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":11319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a grant of restricted stock units that vests on February 21, 2021."}],"balance_after":161195,"source":{"system":"sec-edgar","filing":"0001722482-20-000052","document":"wf-form4_158266972750413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000172248220000052/wf-form4_158266972750413.xml","form_type":"4"}},{"id":3301332,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-27T16:51:03.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2225920,"source":{"system":"sec-edgar","filing":"0001600132-20-000004","document":"wf-form4_158016184529637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000160013220000004/wf-form4_158016184529637.xml","form_type":"4"}},{"id":3513448,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Existing Junior Convertible Preferred","published_at":"2019-05-23T19:28:36.000Z","date":"2019-05-21","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Existing Junior Convertible Preferred Stock automatically converted into common stock of the Issuer upon consummation of the Issuer's initial public offering. The number of shares of common stock received upon conversion of the Existing Junior Convertible Preferred Stock was based on the aggregate liquidation preference of such stock divided by the initial public offering price of $14.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Existing Junior Convertible Preferred Stock automatically converted into common stock of the Issuer upon consummation of the Issuer's initial public offering. The number of shares of common stock received upon conversion of the Existing Junior Convertible Preferred Stock was based on the aggregate liquidation preference of such stock divided by the initial public offering price of $14.00 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Existing Junior Convertible Preferred Stock automatically converted into common stock of the Issuer upon consummation of the Issuer's initial public offering. The number of shares of common stock received upon conversion of the Existing Junior Convertible Preferred Stock was based on the aggregate liquidation preference of such stock divided by the initial public offering price of $14.00 per share."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":117857},"source":{"system":"sec-edgar","filing":"0000899243-19-014603","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000089924319014603/doc4.xml","form_type":"4"}},{"id":3513447,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-23T19:28:36.000Z","date":"2019-05-21","kind":"exercise","acquired":true,"shares":117857,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Existing Junior Convertible Preferred Stock automatically converted into common stock of the Issuer upon consummation of the Issuer's initial public offering. The number of shares of common stock received upon conversion of the Existing Junior Convertible Preferred Stock was based on the aggregate liquidation preference of such stock divided by the initial public offering price of $14.00 per share."}],"balance_after":142001,"source":{"system":"sec-edgar","filing":"0000899243-19-014603","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000089924319014603/doc4.xml","form_type":"4"}},{"id":3513446,"issuer":{"id":3546,"kind":"organization","name":"Avantor, Inc.","symbol":"AVTR"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-23T19:28:36.000Z","date":"2019-05-21","kind":"grant","acquired":true,"shares":14286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a grant of restricted stock units that vests on May 21, 2020."}],"balance_after":24144,"source":{"system":"sec-edgar","filing":"0000899243-19-014603","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000089924319014603/doc4.xml","form_type":"4"}},{"id":3515276,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-22T11:14:37.000Z","date":"2019-05-21","kind":"purchase","acquired":true,"shares":20000,"price":0.6099,"value":12198.0,"ownership":{"direct":true},"balance_after":1875920,"source":{"system":"sec-edgar","filing":"0001600132-19-000085","document":"wf-form4_155853806257021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000160013219000085/wf-form4_155853806257021.xml","form_type":"4"}},{"id":3686776,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-25T16:21:46.000Z","date":"2019-01-25","kind":"purchase","acquired":true,"shares":714286,"price":0.7,"value":500000.2,"ownership":{"direct":true},"balance_after":1855920,"source":{"system":"sec-edgar","filing":"0001600132-19-000043","document":"wf-form4_154845128913147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000160013219000043/wf-form4_154845128913147.xml","form_type":"4"}},{"id":3686775,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-25T16:21:02.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":227273,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1141634,"source":{"system":"sec-edgar","filing":"0001600132-19-000042","document":"wf-form4_154845124603583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000160013219000042/wf-form4_154845124603583.xml","form_type":"4"}},{"id":3973157,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-03T17:40:52.000Z","date":"2018-04-02","kind":"grant","acquired":true,"shares":99010,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":914361,"source":{"system":"sec-edgar","filing":"0001600132-18-000044","document":"wf-form4_152279163964980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000160013218000044/wf-form4_152279163964980.xml","form_type":"4"}},{"id":4191038,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-05T20:28:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":8810,"price":88.79,"value":782239.9,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option provided for vesting in 12 equal monthly installments following June 20, 2017."}],"balance_after":0,"derivative":{"exercise_price":91.21,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":8810},"source":{"system":"sec-edgar","filing":"0001209191-17-056240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000120919117056240/doc4.xml","form_type":"4"}},{"id":4191037,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-05T20:28:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":7000,"price":129.13,"value":903910.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option provided for vesting in 12 equal monthly installments following June 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":50.87,"expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-17-056240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000120919117056240/doc4.xml","form_type":"4"}},{"id":4191036,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-05T20:28:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":120.77,"value":1207700.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option provided for vesting in 12 equal monthly installments following June 9, 2015."}],"balance_after":0,"derivative":{"exercise_price":59.23,"expiration_date":"2025-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-056240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000120919117056240/doc4.xml","form_type":"4"}},{"id":4191035,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-05T20:28:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":178.65,"value":8932500.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option provided for vesting in 36 equal monthly installments commencing April 30, 2014."}],"balance_after":0,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-056240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000120919117056240/doc4.xml","form_type":"4"}},{"id":4191034,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-05T20:28:13.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":1807,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a \"Director Restricted Stock Unit\").  Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000120919117056240/doc4.xml","form_type":"4"}},{"id":4191033,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-05T20:28:13.000Z","date":"2017-10-03","kind":"other","acquired":false,"shares":67932,"price":180,"value":12227760.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F2","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."}],"balance_after":1807,"source":{"system":"sec-edgar","filing":"0001209191-17-056240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000120919117056240/doc4.xml","form_type":"4"}},{"id":4191032,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-05T20:28:13.000Z","date":"2017-09-13","kind":"gift","acquired":false,"shares":635,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":69739,"source":{"system":"sec-edgar","filing":"0001209191-17-056240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000120919117056240/doc4.xml","form_type":"4"}},{"id":4194613,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrants (right to buy)","published_at":"2017-10-03T16:06:41.000Z","date":"2017-09-29","kind":"purchase","acquired":true,"shares":248962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within Units purchased by the reporting person for $1.205 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock."}],"balance_after":248962,"derivative":{"exercise_price":1.242,"exercise_date":"2018-03-29","expiration_date":"2022-09-29","underlying":"Common Stock","underlying_shares":248962},"source":{"system":"sec-edgar","filing":"0001600132-17-000111","document":"wf-form4_150706118735432.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000160013217000111/wf-form4_150706118735432.xml","form_type":"4"}},{"id":4194612,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-03T16:06:41.000Z","date":"2017-09-29","kind":"purchase","acquired":true,"shares":248962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within Units purchased by the reporting person for $1.205 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock."}],"balance_after":815351,"source":{"system":"sec-edgar","filing":"0001600132-17-000111","document":"wf-form4_150706118735432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000160013217000111/wf-form4_150706118735432.xml","form_type":"4"}},{"id":4201601,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-26T16:54:01.000Z","date":"2017-09-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 22, 2017. This option vests in three equal annual installments over a three-year period from the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":1.12,"expiration_date":"2027-09-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001600132-17-000100","document":"wf-form4_150645922823895.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000160013217000100/wf-form4_150645922823895.xml","form_type":"4"}},{"id":4269325,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-30T18:44:18.000Z","date":"2017-06-28","kind":"grant","acquired":true,"shares":57972,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":566389,"source":{"system":"sec-edgar","filing":"0001600132-17-000068","document":"wf-form4_149886264409131.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000160013217000068/wf-form4_149886264409131.xml","form_type":"4"}},{"id":4274578,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-06-22T14:34:40.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":8810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in 12 successive equal monthly installments following the date of grant."}],"balance_after":8810,"derivative":{"exercise_price":91.21,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":8810},"source":{"system":"sec-edgar","filing":"0001209191-17-041302","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000120919117041302/doc4.xml","form_type":"4"}},{"id":4274577,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-22T14:34:40.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":2410,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":70374,"source":{"system":"sec-edgar","filing":"0001209191-17-041302","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000120919117041302/doc4.xml","form_type":"4"}},{"id":4527084,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-12-09T16:28:55.000Z","date":"2016-12-07","kind":"grant","acquired":true,"shares":588373,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option grant was approved by Bellerophon Therapeutics, Inc.'s board of directors on December 7, 2016, subject to stockholder approval of an amendment to the stock option plan under which the option was granted."}],"balance_after":588373,"derivative":{"exercise_price":0.49,"expiration_date":"2026-12-06","underlying":"Common Stock","underlying_shares":588373},"source":{"system":"sec-edgar","filing":"0001628280-16-021961","document":"wf-form4_148131892234661.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000162828016021961/wf-form4_148131892234661.xml","form_type":"4"}},{"id":4538829,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrants (right to buy)","published_at":"2016-11-30T15:31:48.000Z","date":"2016-11-29","kind":"purchase","acquired":true,"shares":285715,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 285,715 Class A Units purchased by the reporting person for $0.70 per Class A Unit. Each Class A Unit consists of one share of common stock and one warrant to purchase one share of common stock."}],"balance_after":285715,"derivative":{"exercise_price":0.8,"exercise_date":"2016-11-29","expiration_date":"2021-11-29","underlying":"Common Stock","underlying_shares":285715},"source":{"system":"sec-edgar","filing":"0001628280-16-021725","document":"wf-form4_148053789553674.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000162828016021725/wf-form4_148053789553674.xml","form_type":"4"}},{"id":4538828,"issuer":{"id":108982,"kind":"organization","name":"Bellerophon Therapeutics, Inc.","symbol":"BLPH"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-30T15:31:48.000Z","date":"2016-11-29","kind":"purchase","acquired":true,"shares":285715,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 285,715 Class A Units purchased by the reporting person for $0.70 per Class A Unit. Each Class A Unit consists of one share of common stock and one warrant to purchase one share of common stock."}],"balance_after":508417,"source":{"system":"sec-edgar","filing":"0001628280-16-021725","document":"wf-form4_148053789553674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500241/000162828016021725/wf-form4_148053789553674.xml","form_type":"4"}},{"id":179721,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"EVP & CFO"}}],"security":"Common Stock","published_at":"2013-10-29T22:22:53.000Z","date":"2013-10-28","kind":"tax_withholding","acquired":false,"shares":13045,"price":116.32,"value":1517394.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 25,000 RSUs which fully vest on 10/28/2014; 10,586 RSUs which vest in one installment of 5,214 on 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017.  Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 347 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan.  DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount."}],"balance_after":94414,"source":{"system":"sec-edgar","filing":"0001127602-13-029956","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213029956/form4.xml","form_type":"4"}},{"id":185017,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"EVP & CFO"}}],"security":"Common Stock","published_at":"2013-04-29T22:10:38.000Z","date":"2013-04-25","kind":"tax_withholding","acquired":false,"shares":2721,"price":104.93,"value":285514.53,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 50,000 RSUs which vest in two equal annual installments of 25,000 each commencing 10/28/2013; 10,586 RSUs which vest in one installment of 5,214 on 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017.  Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 200 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan.  DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount."}],"balance_after":107312,"source":{"system":"sec-edgar","filing":"0001127602-13-014711","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213014711/form4.xml","form_type":"4"}},{"id":187732,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"EVP & CFO"}}],"security":"Common Stock","published_at":"2013-01-31T01:18:18.000Z","date":"2013-01-28","kind":"grant","acquired":true,"shares":7477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include the following RSUs granted under the Company's equity plans: 50,000 RSUs which vest in two equal annual installments of 25,000 each commencing 10/28/2013; 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017.  Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan.  DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount."}],"balance_after":109950,"source":{"system":"sec-edgar","filing":"0001127602-13-003262","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760213003262/form4.xml","form_type":"4"}},{"id":190225,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"EVP & CFO"}}],"security":"Common Stock","published_at":"2012-10-30T00:05:27.000Z","date":"2012-10-28","kind":"tax_withholding","acquired":false,"shares":11671,"price":87.63,"value":1022729.73,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 50,000 RSUs which vest in two equal annual installments of 25,000 each commencing 10/28/2013; 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively.  Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 82 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan.  DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount."}],"balance_after":102438,"source":{"system":"sec-edgar","filing":"0001127602-12-029209","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212029209/form4.xml","form_type":"4"}},{"id":193995,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"EVP & CFO"}}],"security":"Common Stock","published_at":"2012-05-02T01:02:53.000Z","date":"2012-04-27","kind":"grant","acquired":true,"shares":8654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/27/2014, 4/27/2015 and 4/27/2016, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include the following RSUs granted under the Company's equity plans: 75,000 RSUs which vest in three equal annual installments of 25,000 each commencing 10/28/2012; 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively.  Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis."}],"balance_after":114027,"source":{"system":"sec-edgar","filing":"0001127602-12-015259","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760212015259/form4.xml","form_type":"4"}},{"id":198389,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"EVP & CFO"}}],"security":"Common Stock","published_at":"2011-10-31T23:59:07.000Z","date":"2011-10-28","kind":"tax_withholding","acquired":false,"shares":10427,"price":58.06,"value":605391.62,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 75,000 RSUs which vest in three equal annual installments of 25,000 each commencing 10/28/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015.  Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis."}],"balance_after":105373,"source":{"system":"sec-edgar","filing":"0001127602-11-028022","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760211028022/form4.xml","form_type":"4"}},{"id":203488,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"CFO"}}],"security":"Nqso (Right to Buy)","published_at":"2011-04-28T01:16:01.000Z","date":"2011-04-25","kind":"grant","acquired":true,"shares":55125,"price":54.69,"value":3014786.25,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These non-qualified stock options are exercisable in three annual installments of 33%, 33% and 34% on 4/25/2013, 4/25/2014 and 4/25/2015, respectively."}],"balance_after":55125,"derivative":{"exercise_price":54.69,"exercise_date":"2013-04-25","expiration_date":"2021-04-25","underlying":"Common Stock","underlying_shares":55125},"source":{"system":"sec-edgar","filing":"0001127602-11-013890","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760211013890/form4.xml","form_type":"4"}},{"id":203487,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2011-04-28T01:16:01.000Z","date":"2011-04-25","kind":"grant","acquired":true,"shares":15800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/25/2013, 4/25/2014 and 4/25/2015, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include the following RSUs granted under the Company's equity plans: 100,000 RSUs which vest in four equal annual installments of 25,000 each commencing 10/28/2011; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015.  Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis."}],"balance_after":115800,"source":{"system":"sec-edgar","filing":"0001127602-11-013890","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760211013890/form4.xml","form_type":"4"}},{"id":210400,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"CFO"}}],"security":"Nqso (Right to Buy)","published_at":"2010-10-30T00:50:01.000Z","date":"2010-10-28","kind":"grant","acquired":true,"shares":175000,"price":57.27,"value":10022250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are exercisable in four equal annual installments of 25% each commencing October 28, 2011."}],"balance_after":175000,"derivative":{"exercise_price":57.27,"exercise_date":"2011-10-28","expiration_date":"2020-10-28","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001127602-10-026242","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760210026242/form4.xml","form_type":"4"}},{"id":210399,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":12669,"kind":"person","name":"Peacock Jonathan M","position":1,"cik":"0001500241","reported_name":"Peacock Jonathan M","relationship":{"officer":true,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2010-10-30T00:50:01.000Z","date":"2010-10-28","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (RSUs) were granted pursuant to the Company's 2009 Equity Incentive Plan and vest in four equal annual installments of 25% each commencing October 28, 2011.  Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001127602-10-026242","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000112760210026242/form4.xml","form_type":"4"}}]}